



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT APPLICATION**

**TECH CENTER 1600/2900**

**OCT 05 2001**

**RECEIVED**

Applicant(s): Boyle et al.

Serial No.: 09/405,032

Group Art Unit No.: 1647

Filed: September 24, 1999

Examiner: DeBerry, R.

For: Osteoprotegerin

Docket No.: A-378CIP2C2

**RESPONSE TO OFFICE ACTION**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Office Action dated March 28, 2001 in which Claims 61-68 are rejected under 35 U.S.C. 112. Reconsideration and withdrawal of the rejections are requested.

Please amend the application as follows:

**In the Specification:**

At page 4, replace the third paragraph, lines 25-31, with the following:

cl  
Figure 1. A. (SEQ ID NOS: 169 & 170) FASTA analysis of novel EST LORF. Shown is the deduced FRI-1 amino acid sequence aligned to the human TNFR-2 sequence. B. (SEQ ID NOS: 119 & 171) Profile analysis of the novel EST LORF shown is the deduced FRI-1 amino acid sequence aligned to the TNFR-profile. C. Structural view of TNFR superfamily indicating region which is homologous to the novel FRI-1.

At page 4, replace the fourth paragraph, lines 33-36 and page 5, first paragraph, lines 1-12 with the following:

10/04/2001 BSAYAS11 00000014 010519 09405032

01 FC:117 890.00 CH

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EL36069028US

Date of Deposit: September 28, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Box Response, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum

Printed Name

*Lynne Buchsbaum*  
Signature